Delivra Health BrandsDHBUF -0.29%28 PS Ratio is 0.27 as of Jul. 07, 2026, which is 82% below its 10-year median of 1.51. GuruFocus rates DHBUF with a GF Score™ of 28/100 and a GF Value™ of $0.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, Delivra Health Brands ranks better than 93.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Delivra Health Brands's share price is $0.0699.
Delivra Health Brands's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.26. Hence, Delivra Health Brands's PS Ratio for today is 0.27.
Good Sign:
Delivra Health Brands Inc stock PS Ratio (=0.31) is close to 10-year low of 0.28.
The historical rank and industry rank for Delivra Health Brands's PS Ratio or its related term are showing as below:
DHBUF'
s PS Ratio Range Over the Past 10 Years
Min: 0.28 Med: 1.51 Max: 866.67
Current: 0.31
During the past 13 years, Delivra Health Brands's highest PS Ratio was 866.67. The lowest was 0.28. And the median was 1.51.
DHBUF's PS Ratio is ranked better than 93.8% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs DHBUF: 0.31
Delivra Health Brands Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Delivra Health Brands was -6.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 13 years, Delivra Health Brands's highest 3-Year average Revenue per Share Growth Rate was 196.00% per year. The lowest was -1.10% per year. And the median was 8.55% per year.
Back to Basics: PS Ratio
Delivra Health Brands (OTCPK:DHBUF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Delivra Health Brands's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delivra Health Brands PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Delivra Health Brands's PS Ratio distribution charts can be found below:
* The bar in red indicates where Delivra Health Brands's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Delivra Health Brands's Share Price of today is $0.0699. Delivra Health Brands's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Delivra Health Brands (DHBUF) has a PS Ratio of 0.27 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Delivra Health Brands and its competitors. This is 82% below median its historical median of 1.51. Over the past decade, Delivra Health Brands' PS Ratio has ranged from 0.28 to 866.67. According to the industry distribution chart, Delivra Health Brands ranks #59 out of 952 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Delivra Health Brands' PS Ratio too high?
Delivra Health Brands' current PS Ratio of 0.27 is 82% below median its 10-year median of 1.51. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 866.67. The Drug Manufacturers industry median PS Ratio is 2.32. Delivra Health Brands' value of 0.27 is 88.3% below this industry median. Based on the distribution chart, Delivra Health Brands ranks #59 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Delivra Health Brands has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Delivra Health Brands' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Delivra Health Brands ranks #59 out of 952 companies for PS Ratio. This places Delivra Health Brands in the top 6% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.32. Delivra Health Brands' value of 0.27 is 88.3% below this benchmark. Historically, Delivra Health Brands' own PS Ratio has ranged from 0.28 to 866.67 over the past decade. While the company's 10-year median is 1.51 vs. the industry median of 2.32, Delivra Health Brands has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delivra Health Brands's current PS Ratio of 0.27 is 88.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Delivra Health Brands and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delivra Health Brands's current PS Ratio is 0.27, which is 82% below median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (DHBUF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.07 — trading 63.2% below its estimated fair value. The current PS Ratio is 0.27, which is 82% below median its 10-year median of 1.51 and 88.3% below the Drug Manufacturers industry median of 2.32. Delivra Health Brands' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Delivra Health Brands (DHBUF), the current PS Ratio is 0.27 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delivra Health Brands (DHBUF) Overvalued in 2026?
Based on GuruFocus' analysis, Delivra Health Brands stock appears to be undervalued.
The current stock price of $0.07 is trading 63.2% below its estimated GF Value™ of $0.19.
GuruFocus considers Delivra Health Brands to be Possible Value Trap.
Key valuation signals for DHBUF:
PS Ratio: 0.27 (82% below median its 10-year median of 1.51)
GF Value™: $0.19 vs. price of $0.07 (63.2% below fair value)
Industry Position: 88.3% below the Drug Manufacturers median (#59 of 952)
No single metric tells the full story. See the DHBUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.
28GF Score
Get the complete analysis for DHBUF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHBUF has been successfully added to your 
